Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rabphilin-3A is a synaptic vesicle-associated effector protein with multiple functional domains. It was originally identified as a binding partner of the small GTPases Rab3A and Rab27A, which localize to secretory vesicles in neurons and neuroendocrine cells. Rabphilin-3A interacts with GTP-bound Rab proteins via its N-terminal Rab-binding domain and links vesicles to the actin cytoskeleton through α-actinin binding. Its C-terminal C2 domains bind calcium, phospholipids, and SNAP-25. Rabphilin-3A's main biological role is to regulate both exocytosis and endocytosis of vesicles, especially facilitating SNARE complex assembly for neurotransmitter release. It acts at distinct stages in the vesicular trafficking pathway, influencing vesicle docking, fusion, and membrane retrieval, but does not function as a receptor, enzyme, transporter, or transcription factor[1][2].
Not applicable; drugs do not directly target this molecule. Its mechanism involves regulation of vesicle docking and fusion through protein-protein interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rabphilin-3A (RPH3A).